🇺🇸 FDA
Patent

US 11883383

Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine

granted A61KA61K31/4164A61P

Quick answer

US patent 11883383 (Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine) held by VTV THERAPEUTICS LLC expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VTV THERAPEUTICS LLC
Grant date
Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/4164, A61P, A61P25/28